These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 36559226)

  • 1. New and Old Horizons for an Ancient Drug: Pharmacokinetics, Pharmacodynamics, and Clinical Perspectives of Dimethyl Fumarate.
    Matteo P; Federico D; Emanuela M; Giulia R; Tommaso B; Alfredo G; Anna C; Annamaria O
    Pharmaceutics; 2022 Dec; 14(12):. PubMed ID: 36559226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety.
    Dubey D; Kieseier BC; Hartung HP; Hemmer B; Warnke C; Menge T; Miller-Little WA; Stuve O
    Expert Rev Neurother; 2015 Apr; 15(4):339-46. PubMed ID: 25800129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dimethyl Fumarate and Its Esters: A Drug with Broad Clinical Utility?
    Kourakis S; Timpani CA; de Haan JB; Gueven N; Fischer D; Rybalka E
    Pharmaceuticals (Basel); 2020 Oct; 13(10):. PubMed ID: 33066228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dimethyl fumarate (DMF) vs. monoethyl fumarate (MEF) salts for the treatment of plaque psoriasis: a review of clinical data.
    Landeck L; Asadullah K; Amasuno A; Pau-Charles I; Mrowietz U
    Arch Dermatol Res; 2018 Aug; 310(6):475-483. PubMed ID: 29574575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dimethyl fumarate for multiple sclerosis.
    Xu Z; Zhang F; Sun F; Gu K; Dong S; He D
    Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD011076. PubMed ID: 25900414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination treatment with secukinumab and dimethyl fumarate in a patient with psoriasis and recent diagnosis of multiple sclerosis.
    Di Tullio F; Odorici G; Lasagni C; Capobianco M; Conti A; Mandel VD
    Dermatol Ther; 2020 Nov; 33(6):e13943. PubMed ID: 32614114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dimethyl fumarate is efficacious in severe plaque psoriasis : Post hoc analysis from the BRIDGE trial in Austria.
    Sator P; Loewe R; Zamani O; Holzer G; Wolf P; Mlynek A; Berger T; Richter L; Schuller E
    Wien Klin Wochenschr; 2019 Oct; 131(19-20):485-492. PubMed ID: 31591676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Pediatric Patients With Relapsing Multiple Sclerosis (FOCUS).
    Alroughani R; Das R; Penner N; Pultz J; Taylor C; Eraly S
    Pediatr Neurol; 2018 Jun; 83():19-24. PubMed ID: 29681490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dimethyl fumarate for treating relapsing multiple sclerosis.
    Sheremata W; Brown AD; Rammohan KW
    Expert Opin Drug Saf; 2015 Jan; 14(1):161-70. PubMed ID: 25382392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dimethyl fumarate induced lymphopenia in multiple sclerosis: A review of the literature.
    Dello Russo C; Scott KA; Pirmohamed M
    Pharmacol Ther; 2021 Mar; 219():107710. PubMed ID: 33091427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BG 12: BG 00012, BG 12/Oral Fumarate, FAG-201, second-generation fumarate derivative--Fumapharm/Biogen Idec.
    Drugs R D; 2005; 6(4):229-30. PubMed ID: 15991882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis.
    Burness CB; Deeks ED
    CNS Drugs; 2014 Apr; 28(4):373-87. PubMed ID: 24623127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A safety evaluation of dimethyl fumarate in moderate-to-severe psoriasis.
    Reszke R; Szepietowski JC
    Expert Opin Drug Saf; 2020 Apr; 19(4):373-380. PubMed ID: 32129112
    [No Abstract]   [Full Text] [Related]  

  • 14. Dimethyl Fumarate: A Review in Moderate to Severe Plaque Psoriasis.
    Blair HA
    Drugs; 2018 Jan; 78(1):123-130. PubMed ID: 29236231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilization of Dimethyl Fumarate and Related Molecules for Treatment of Multiple Sclerosis, Cancer, and Other Diseases.
    Al-Jaderi Z; Maghazachi AA
    Front Immunol; 2016; 7():278. PubMed ID: 27499754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate.
    Nicholas JA; Boster AL; Imitola J; O'Connell C; Racke MK
    Drug Des Devel Ther; 2014; 8():897-908. PubMed ID: 25045248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial.
    Svenningsson A; Frisell T; Burman J; Salzer J; Fink K; Hallberg S; Hambraeus J; Axelsson M; Nimer FA; Sundström P; Gunnarsson M; Johansson R; Mellergård J; Rosenstein I; Ayad A; Sjöblom I; Risedal A; de Flon P; Gilland E; Lindeberg J; Shawket F; Piehl F; Lycke J
    Lancet Neurol; 2022 Aug; 21(8):693-703. PubMed ID: 35841908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antipsoriatic dimethyl-fumarate suppresses interferon-gamma -induced ICAM-1 and HLA-DR expression on hyperproliferative keratinocytes. Quantification by a culture plate-directed APAAP-ELISA technique.
    Sebok B; Bonnekoh B; Vetter R; Schneider I; Gollnick H; Mahrle G
    Eur J Dermatol; 1998; 8(1):29-32. PubMed ID: 9649687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunity.
    Liebmann M; Korn L; Janoschka C; Albrecht S; Lauks S; Herrmann AM; Schulte-Mecklenbeck A; Schwab N; Schneider-Hohendorf T; Eveslage M; Wildemann B; Luessi F; Schmidt S; Diebold M; Bittner S; Gross CC; Kovac S; Zipp F; Derfuss T; Kuhlmann T; König S; Meuth SG; Wiendl H; Klotz L
    Brain; 2021 Nov; 144(10):3126-3141. PubMed ID: 34849598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dimethyl fumarate (Tecfidera): a new oral agent for multiple sclerosis.
    Venci JV; Gandhi MA
    Ann Pharmacother; 2013 Dec; 47(12):1697-702. PubMed ID: 24259625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.